Compass Therapeutics Stock Cash Flow From Operations
| CMPX Stock | USD 3.40 0.33 10.75% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Compass Therapeutics' long-term financial health and intrinsic value.
Compass | Cash Flow From Operations | Build AI portfolio with Compass Stock |
Compass Therapeutics Company Cash Flow From Operations Analysis
Compass Therapeutics' Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Compass Therapeutics Cash Flow From Operations | (44.85 M) |
Most of Compass Therapeutics' fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Compass Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Compass Cash Flow From Operations Driver Correlations
Understanding the fundamental principles of building solid financial models for Compass Therapeutics is extremely important. It helps to project a fair market value of Compass Stock properly, considering its historical fundamentals such as Cash Flow From Operations. Since Compass Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Compass Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Compass Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
| Competition |
In accordance with the recently published financial statements, Compass Therapeutics has (44.85 Million) in Cash Flow From Operations. This is 108.51% lower than that of the Biotechnology sector and 171.74% lower than that of the Health Care industry. The cash flow from operations for all United States stocks is 104.62% higher than that of the company.
Compass Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Compass Therapeutics' direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Compass Therapeutics could also be used in its relative valuation, which is a method of valuing Compass Therapeutics by comparing valuation metrics of similar companies.Compass Therapeutics is currently under evaluation in cash flow from operations category among its peers.
Compass Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Compass Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Compass Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Compass Fundamentals
| Return On Equity | -0.41 | ||||
| Return On Asset | -0.26 | ||||
| Operating Margin | (72.73) % | ||||
| Current Valuation | 318.27 M | ||||
| Shares Outstanding | 138.28 M | ||||
| Shares Owned By Insiders | 14.16 % | ||||
| Shares Owned By Institutions | 67.97 % | ||||
| Number Of Shares Shorted | 7.39 M | ||||
| Price To Book | 3.85 X | ||||
| Price To Sales | 499.44 X | ||||
| Revenue | 850 K | ||||
| Gross Profit | 850 K | ||||
| EBITDA | (54.87 M) | ||||
| Net Income | (49.38 M) | ||||
| Cash And Equivalents | 132.02 M | ||||
| Cash Per Share | 1.31 X | ||||
| Total Debt | 6.63 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 12.36 X | ||||
| Book Value Per Share | 0.80 X | ||||
| Cash Flow From Operations | (44.85 M) | ||||
| Short Ratio | 7.86 X | ||||
| Earnings Per Share | (0.40) X | ||||
| Target Price | 13.22 | ||||
| Number Of Employees | 35 | ||||
| Beta | 1.28 | ||||
| Market Capitalization | 424.53 M | ||||
| Total Asset | 140.4 M | ||||
| Retained Earnings | (364.68 M) | ||||
| Working Capital | 123.88 M | ||||
| Net Asset | 140.4 M |
About Compass Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Compass Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Compass Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Compass Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Compass Stock Analysis
When running Compass Therapeutics' price analysis, check to measure Compass Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Compass Therapeutics is operating at the current time. Most of Compass Therapeutics' value examination focuses on studying past and present price action to predict the probability of Compass Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Compass Therapeutics' price. Additionally, you may evaluate how the addition of Compass Therapeutics to your portfolios can decrease your overall portfolio volatility.